Compare LC & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LC | GLPG |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | N/A | N/A |
| Metric | LC | GLPG |
|---|---|---|
| Price | $15.96 | $34.44 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | $22.67 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 2.7M | 98.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.76 |
| Revenue Next Year | $15.91 | $0.49 |
| P/E Ratio | $13.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.90 | $22.59 |
| 52 Week High | $21.67 | $37.78 |
| Indicator | LC | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 58.89 |
| Support Level | $15.00 | $33.39 |
| Resistance Level | $17.63 | $34.22 |
| Average True Range (ATR) | 1.00 | 0.62 |
| MACD | -0.16 | -0.05 |
| Stochastic Oscillator | 28.16 | 77.84 |
LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.